Human Lung Mast Cells: Therapeutic Implications in Asthma

Abstract

Mast cells are strategically located in different compartments of the lung in asthmatic patients. These cells are widely recognized as central effectors and immunomodulators in different asthma phenotypes. Mast cell mediators activate a wide spectrum of cells of the innate and adaptive immune system during airway inflammation. Moreover, these cells modulate the activities of several structural cells (i.e., fibroblasts, airway smooth muscle cells, bronchial epithelial and goblet cells, and endothelial cells) in the human lung. These findings indicate that lung mast cells and their mediators significantly contribute to the immune induction of airway remodeling in severe asthma. Therapies targeting mast cell mediators and/or their receptors, including monoclonal antibodies targeting IgE, IL-4/IL-13, IL-5/IL-5Rα, IL-4Rα, TSLP, and IL-33, have been found safe and effective in the treatment of different phenotypes of asthma. Moreover, agonists of inhibitory receptors expressed by human mast cells (Siglec-8, Siglec-6) are under investigation for asthma treatment. Increasing evidence suggests that different approaches to depleting mast cells show promising results in severe asthma treatment. Novel treatments targeting mast cells can presumably change the course of the disease and induce drug-free remission in bronchial asthma. Here, we provide an overview of current and promising treatments for asthma that directly or indirectly target lung mast cells.

1. Introduction

Mast cells, first identified in humans by Paul Ehrlich in 1878 [1], play a role in allergic [2,3] and autoimmune disorders [4], microbial infections [5], cardiovascular diseases [6,7], immunodeficiencies [8], and cancer [9,10,11]. Mast cells are derived from CD34⁺ haemopoietic progenitors that migrate from the bone marrow to the blood and mature in almost all tissues [12]. These cells release a plethora of mediators and display several surface receptors [13,14]. Mast cells uniquely express the cell surface receptor of stem cell factor (SCF) [15], also known as KIT or CD117. SCF plays a critical role in the differentiation, proliferation, and modulation of human and rodent mast cells [16].

In the 1990s, human mast cells that contain only tryptase were termed MCT, whereas those that express both tryptase and chymase were classified as MCTC [17,18]. There are also definitions of mast cells being inflammatory, pro-, or anti-tumorigenic [19,20,21]. The transcriptional profiles of mast cells clearly demonstrate the heterogeneity of mast cells and their different gene expression [14,22,23,24]. Moreover, human mast cells analyzed ex vivo or differentiated in vitro showed significant differences [24]. Human and mouse mast cells have distinct proteomes and unique gene expressions compared to other immune cells [22,25]. Single-cell transcriptomics of human lungs provide evidence of mast cells [26,27]. Different triggers (e.g., IgE-mediated or IL-33) can induce distinct genomic and transcriptional changes in human mast cells [28]. Individual mast cells are exposed to their local environment (e.g., cytokines, different pH, growth factors, etc.) and, over time, are tuned by many different activating and inhibitory signals. Mast cells in different organs differ in their receptor and mediator expression, but there is also considerable heterogeneity among human lung mast cells [29]. It is possible to speculate that individual mast cells could all be unique to some extent.

In this review, we provide an overview of current and promising treatments for asthma that directly or indirectly target lung mast cells.

2. Activating and Inhibitory Receptors on Human Mast Cells

Human mast cells display a wide spectrum of cell surface receptors that can be activated by several immunologic and non-immunologic stimuli that modulate their development and effector functions [11,30]. Figure 1 schematically illustrates the main activating and inhibitory receptors on human lung mast cells relevant to bronchial asthma.

Activation of human lung mast cells releases a vast arsenal of preformed and newly synthesized lipid mediators, cytokines, chemokines, angiogenic, and lymphangiogenic factors [88] (Table 1).

3. Role of Mast Cells in Asthma

FcεRI cross-linking by allergens, anti-IgE, or super allergens results in the release of histamine, cytokines/chemokines, enzymes such as tryptase and chymase, and the generation of eicosanoids (i.e., LTC₄ and PGD₂) from human mast cells [32,134]. Mast cell-derived mediators are responsible for bronchoconstriction, airway inflammation, and remodeling in different asthma endotypes [2]. The density of mast cells within airway smooth muscle (ASM) bundles is increased in asthmatic patients compared to controls [90]. There is an inverse correlation between the number of mast cells in the ASM and airway hyperresponsiveness (AHR) in asthmatics [90]. HLMCs adhere avidly to ASM cells [135], which favor mast cell survival and activation [136]. Elevated circulating mast cell progenitors are correlated with reduced lung function in allergic asthma [137]. The rapid IgE-dependent release of histamine and eicosanoids (e.g., LTC₄ and PGD₂) from isolated HLMCs [138] correlates with these mediators in bronchoalveolar lavage fluids following bronchial allergen challenge [139,140,141]. Histamine can promote mucus secretion and bronchoconstriction. Asthma is accompanied by airway remodeling [142] and angiogenesis [143,144], and lung mast cells may contribute to this by the release of several cytokines, chemokines [88], and VEGFs [58,126,145,146]. Submucosal mast cells, which are abundant in healthy controls, are shifted from the submucosal compartment to the epithelium in asthma [147]. IL-33-activated mast cells increase the expression of epithelial IL33, which in turn upregulates the production of type-2 cytokines (i.e., IL-5, IL-13, IL-4) in mast cells. These findings demonstrate a shift in the location of mast cells to the epithelium in asthma and identify intraepithelial mast cells as critical modulators of inflammation in asthma. Psychological stress is thought to induce mast cell activation via the stimulation of peripheral nerves and the release of substance P and corticotropin-release hormone (CRH) [148]. Human mast cells express CRH receptors and their activation induces the selective release of VEGF-A without degranulation [149]. These findings provide a hypothetical link between stress, mast cell activation, and asthma exacerbations [150]. The role of HLMCs in inducing the symptoms of human airway inflammation is also supported by the efficacy of drugs, which block either their function or target mediators primarily released by these cells.

Figure 2 schematically illustrates the multiple interactions between HLMCs and several cells of the innate and adaptive immune system through the release of mediators. HLMCs can also interact with non-immune cells involved in bronchial asthma (Figure 3).

4. Mast Cell-Targeted Treatments for Bronchial Asthma

4.1. Histamine Receptors

Although second-generation H1 antihistamines are widely used for the treatment of allergic rhinitis and urticaria [152,153], their therapeutic role in asthma is marginal. Histamine H₄ receptor mediates chemotaxis of HLMCs [154]. In preclinical models, H4 receptor antagonists (e.g., JNJ39758979, ZPL-3893787, and toreforant) exhibited some anti-inflammatory effects. Some have been tested in randomized control trials (RCTs) for allergic diseases with mixed results [155,156,157].

4.2. Tryptase

Circulating β-tryptase levels were increased in asthmatics independently of type 2 inflammation and associated with lesser omalizumab response [92]. MTPS9579A, a mAb that inhibits the activity of tryptase, is in a phase II trial in patients with moderate-to-severe asthma (NCT04092582). E104 and 31A.v11 are anti-tryptase mAbs showing promising effects in preclinical models of allergic reactions [92,158].

4.3. Prostaglandin D₂

PGD₂, the major cyclooxygenase mediator synthesized by HLMCs, activates the CRTh2 on T helper 2 cells (Th2 cells) [159]. Several CRTh2 antagonists [i.e., fevipiprant, timapiprant (OC-459), AZD1981, BI671800, and setipiprant] failed to show efficacy in asthma and allergic rhinitis patients. In particular, fevipiprant was not effective in phase III trials in asthmatics [160]. GB001, a novel CRTh2 antagonist, was well tolerated and resulted in some benefits in reducing asthma exacerbations [161].

4.4. Cysteinyl Leukotrienes

Leukotriene inhibitors (i.e., montelukast, zafirlukast, pranlukast, and zileuton) have been used with mixed results in allergic diseases. Montelukast, approved by the Food and Drug Administration (FDA) for the treatment of asthma and allergic rhinitis [162], is less effective compared to inhaled or intranasal glucocorticoids [163]. AZD5718, a reversible 5-lipoxygenase activating protein (FLAP) that suppresses leukotriene synthesis, is currently in Phase II trial for moderate-to-severe asthma treatment compared to montelukast (NCT05251259).

4.5. Mast Cell Cytokines and Their Receptors

IL-13 and IL-5 are produced by HLMCs [107]. Phase III studies demonstrated that two anti-IL-13 mAbs, lebrikizumab [164] and tralokinumab [165,166], did not reduce asthma exacerbation rates but did improve lung function in patients with severe asthma [166,167,168]. In contrast, dupilumab, a mAb which is a dual inhibitor of IL-4 and IL-13 through blockade of their shared IL-4Rα subunit, is approved for the treatment of severe uncontrolled asthma and chronic rhinosinusitis with nasal polyps [169,170,171]. The anti-IL-5 mAbs, mepolizumab [172,173] and reslizumab [174], and the anti-IL-5Rα mAb benralizumab [175] are approved as add-on therapy for the treatment of severe eosinophilic asthma [176]. These drugs markedly deplete blood eosinophils and decrease the frequency of asthma exacerbations and improve lung function in patients with severe uncontrolled asthma [174,177,178]. TNF-α is released by mouse mast cells [5], but its production by HLMCs is still controversial. Golimumab, a human mAb anti-TNF-α, showed an increase in adverse events and inconsistent efficacy in severe asthma patients [179].

A mAb anti-IL-17R, brodalumab, did not demonstrate efficacy in asthma [180]. Although mast cells are a major source of several cytokines, their production of other cytokines (i.e., IL-17A) may be selectively restricted to mast cell subtypes (e.g., synovial and skin mast cells [181]). Mast cells are also a source of IL-23 and express IL-23R [181]. Risankizumab, a mAb anti-IL-23, showed increased asthma worsening in a phase 2a trial [182].

4.6. Alarmins and Their Receptors

There is increasing evidence that bronchial epithelial cells represent not only a physical barrier but also an immune organ, which plays a central role in asthma pathobiology [183,184]. TSLP, IL-33, and IL-25 are upstream epithelial-derived cytokines, collectively known as alarmins [40,43,185]. These cytokines also activate downstream a broad range of cellular targets, including mast cells, to propagate the release of several cytokines involved in asthma [40].

4.7. Tezepelumab

Tezepelumab is a human IgG2λ mAb, which binds to TSLP, which is involved in different asthma phenotypes [40]. TSLP is overexpressed by the airway epithelium of asthmatics [115]. TSLP levels are increased in the BAL fluid of asthmatics [186] and serum during asthma exacerbations [187]. Tezepelumab was recently approved by the FDA and European Medicines Agency (EMA) for severe asthma treatment with no phenotype or biomarker limitations. In RCTs, tezepelumab reduced annual exacerbation rates regardless of blood eosinophil count, with an increase in prebronchodilator FEV₁ compared to the placebo group [188,189]. In two different RCTs, tezepelumab reduced AHR, suggesting an effect on lung mast cell activation [190,191]. TSLP can promote airway remodeling in asthma through different mechanisms: it activates human lung fibroblasts [192] and causes angiogenic and lymphangiogenic factor release from HLMs [193]. In the phase II CASCADE study, the effects of tezepelumab on airway remodeling were examined in moderate-to-severe asthmatics [190]. Tezepelumab reduced airway submucosal eosinophils compared to placebo. A human mAb anti-TSLP (HBM9378) [194] and an inhaled antibody fragment against TSLP (CSJ117) [195] (NCT03138811; NCT04410523; NCT04946318) are under development for asthma treatment. Figure 4 schematically illustrates the inhibition of mast cell activation by different biologics and drugs.

4.8. Itepekimab

Itepekimab is a human IgG4 mAb that binds to IL-33. In a phase 2 trial, the safety and efficacy of itepekimab, dupilumab, itepekimab plus dupilumab, or placebo were compared in moderate-to-severe asthmatics [200]. Loss of asthma control was similar in the three groups but better than in the placebo. Itepekimab and dupilumab monotherapies increased pre-bronchodilator FEV₁, reduced peripheral blood eosinophils, and improved asthma control and quality of life compared to placebo.

4.9. Astegolimab and Etokimab

Astegolimab is a human IgG2 mAb that targets ST2, the IL-33 receptor, and blocks IL-33 signaling [46,202]. In the phase 2b ZENYATTA study, astegolimab was well-tolerated and reduced the number of exacerbation rates in severe asthma patients [202]. Astegolimab did not significantly modify FEV₁ compared to placebo in the entire population of asthmatics. FEV1 improvement appeared to be higher in patients with low blood eosinophils.

Etokimab (ANB020) is a humanized mAb that binds to IL-33. A preliminary study found that etokimab has the potential to desensitize subjects allergic to peanuts [201].

4.10. Tozorakimab

Tozorakimab (formerly MEDI3506) is a mAb that binds to IL-33 [216]. RCTs are evaluating the safety and efficacy of tozorakimab compared to placebo in adults with moderate-to-severe asthma (NCT04570657) and chronic obstructive pulmonary disease (COPD) with a history of exacerbations (NCT05166889).

mAbs blocking IL-25 have shown beneficial effects in a mouse model of allergic asthma [217].

4.11. FcεRI and IgE

Omalizumab, a humanized IgG1-k mAb that binds to Fcε, was the first mAb approved by the FDA for the treatment of patients with moderate and severe asthma [218]. It binds to free IgE and inhibits the IgE–FcεRI interaction by preventing the binding of IgE to FcεRI on human mast cells and basophils. Omalizumab also downregulates FcεRI expression [219]. Omalizumab did not improve FEV₁ in RCTs [220,221,222], but there is some evidence that it can improve FEV₁ in real-life settings [212,222]. It reduces asthma symptoms and exacerbations [223,224,225].

Ligelizumab is a second-generation humanized anti-IgE mAb, which has a higher affinity for the Cε3 domain of IgE compared to omalizumab and may affect IgE production by B cells [213]. Ligelizumab failed to meet the primary endpoints in phase II clinical trials of asthma, and it was discontinued (NCT02075008, NCT02336425). The safety and efficacy of ligelizumab are presently investigated in chronic urticaria (NCT05024058, NCT04513548, NCT03580356, NCT03580369, NCT02477332, NCT04903613). There are several promising compounds targeting FcεRI and/or IgE under investigation. GI-301, an IgE trap-Fc fusion protein, and the anti-IgE mAb UB-221 showed higher affinity to IgE compared to omalizumab (NCT05298215). Combined treatment with omalizumab and omalizumab-resistant IgE–Fc fragment (IgE-R419N-Fc3-4 mutant) caused more inhibition of basophil activation than either agent alone [226]. It has been proposed that exon skipping of the β-subunit of FcεRI in mast cells eliminated FcεRI expression and function in these cells [227].

4.12. Intracellular Signaling Pathways

Several promising small molecular weight compounds target intracellular signaling pathways, including spleen tyrosine kinase (SYK), Bruton’s tyrosine kinase (BTK), and Janus kinase (JAK), to block mast cell activation [214,228,229]. SYK inhibitors (i.e., fostamatinib, LAS189386, TAS05567, BAY61-3606) and aerosolized SYK antisense oligodeoxynucleotides block mast cell degranulation and inhibit models of allergic disorders [230,231,232,233]. SYK inhibitors also inhibit IgE-mediated contraction of human lung slices and histamine and leukotriene release [234]. The intranasal SYK inhibitor R112 improved symptoms in seasonal rhinitis patients [235,236].

Several BTK inhibitors are used for the management of hematological tumors [237] and are in development for the treatment of mast cell-driven diseases, including acalabrutinib for anaphylaxis [238] (NCT05038904), remibrutinib for CSU and food allergy (NCT05432388, NCT05032157, NCT05170724, NCT05513001), fenebrutinib for CSU (NCT036933625), and ibrutinib for food allergy [239] and anaphylaxis (NCT03149315). Concern has risen regarding the risk of cardiovascular adverse events associated with BTK inhibitors [237].

A phase I study assessed the safety and efficacy of GDC-0214, an inhaled JAK inhibitor, in adults with mild asthma [214]. This compound caused a dose-dependent reduction in fractional exhaled nitric oxide (FeNo) in patients with mild asthma. Additional studies on the effects of JAK inhibitors are expected for asthma treatment [240].

4.13. Silencing Mast Cells

Mast cells display several inhibitory receptors (i.e., Siglec-8, Siglec-6, CD200R, CD300a, and FcγRIIb) which inhibit mast cell activation [71]. An anti-Siglec-8 antibody inhibited anaphylaxis in humanized mice and IgE-dependent and IgE-independent activation of human mast cells in lung tissues [241,242,243]. Lirentelimab (AK002), a humanized anti-Siglec-8 mAb, showed promising activity in eosinophilic gastritis and duodenitis [244]. RCTs in eosinophilic esophagitis (NCT04322708), allergic conjunctivitis (NCT03379311), chronic urticaria (NCT03436797), and indolent systemic mastocytosis (NCT02808793) are ongoing. Lirentelimab reduced circulating eosinophil and tissue mast cells in eosinophilic gastrointestinal disease patients [245]. Lirentelimab depletes sputum eosinophils from asthmatic subjects and inhibits FcεRI-mediated HLMC activation [242]. Lirentelimab is presently under investigation in patients with atopic dermatitis (NCT05155085), CSU (NCT05528861), and eosinophilic duodenitis (NCT04856891).

AK006, a humanized IgG1 agonistic Siglec-6 mAb, inhibits mast cell activation in vitro. Interestingly, co-culturing human mast cells with macrophages in the presence of AK006 induces antibody-dependent phagocytosis of mast cells [215]. These findings represent a novel strategy to selectively reduce mast cells via Siglec-6 targeting.

LY3454738, a CD200R agonist, is under development for atopic dermatitis and CSU. Bispecific antibodies that cross-link either IgE [246] or KIT [247] and CD300a, and co-aggregate FcεRI with FcγRIIb, inhibited FcεRI-induced or KIT-induced signaling. An engineered protein inhibitor, designed ankyrin repeat protein (DARPin) E2-79 blocks IgE- FcεRI interactions and favors the dissociation of preformed ligand (IgE)-FcεRI complexes. Anti-IgE DARPin-Fc fusion protein inhibits allergen-induced basophil activation [248,249].

4.14. Depleting Mast Cells

Human mast cells express high levels of KIT throughout their development [16]. Activation of KIT by SCF influences several aspects of mast cell responses. Dysregulation of the SCF/KIT pathway markedly alters mast cell homeostasis. For instance, loss-of-function mutations in SCF or KIT result in mast cell deficiency; in contrast, gain-of-function mutations in KIT lead to mast cell hyperplasia and activation, as found in mastocytosis [250,251,252]. The blockage of the SCF/KIT pathway has been investigated in several models of allergic disorders [253,254,255,256,257]. A bispecific antibody cross-linking KIT and CD300a [247] inhibit SCF-induced human mast cell differentiation and survival and skin reactions induced by SCF in mice [247].

Mast cell apoptosis can be achieved via neutralization of the effects of SCF and/or blockage of its receptor KIT (CD117) (Figure 5). CDX-0159 (Celldex Therapeutics, NJ, USA) is a humanized mAb that binds to the extracellular dimerization domain of KIT [258,259]. This mAb is under investigation in CSU (NCT04538794) and chronic inducible urticaria (NCT04548869). In a phase Ia trial, CDX-0159 administration showed a favorable safety profile and caused a marked reduction of peripheral blood tryptase, suggestive of systemic mast cell depletion (NCT04146129). It remains to be evaluated whether this mAb may work in experimental models of asthma [256].

Another approach to block KIT signaling in mast cells is to use specific tyrosine kinase inhibitors (TKIs) (Figure 5). There are several classes of KIT-targeting TKIs, which display distinct pharmacologic characteristics on human mast cells in vitro [260]. KIT-targeting drugs can inhibit mast cell activation and mediator-induced symptoms in allergic disorders [265,266,267,268]. There are very preliminary data on the in vivo efficacy of KIT-specific or multitargeted TKIs in the treatment of patients with severe allergic disorders (e.g., severe asthma). The administration of masitinib to patients with severe glucocorticoid-dependent asthma was associated with steroid-sparing effects [264]. Imatinib did not influence lung function. In another study, imatinib reduced airway hyperresponsiveness in patients with severe asthma compared to controls [262].

In a phase III trial, masitinib reduced asthma exacerbations compared to placebo in severe asthma patients [263]. Avapritinib (BLU-285), a potent inhibitor of mutant KIT and PDGFRA with activation loop mutations, induces mast cell cytoreduction and remission in the majority of advanced systemic mastocytosis patients [269,270]. It should be emphasized that some of these TKIs also inhibit IgE-dependent basophil activation [271,272,273]. This is relevant because basophils play a role in allergic disorders [88,274]. Future studies should evaluate the safety and efficacy of imatinib, masitinib, and possibly newer TKIs in patients with different phenotypes of severe asthma.

5. Discussion and Conclusions

Human mast cells were identified and named over 140 years ago by Paul Ehrlich [1]. IgE was discovered by Kimishige and Teruko Ishizaka [275] and Gunnar Johansson [276]. The approval of omalizumab, the first mAb anti-IgE for the treatment of asthma in 2003, was a breakthrough in the treatment of patients with mast cell-driven diseases, such as asthma and CSU. Since then, several biologics targeting mast cells directly or indirectly have been approved for the treatment of severe asthma. In particular, mAbs targeting IL-5 (mepolizumab [204,205,206,207] and reslizumab [208,209]), IL-5Rα (benralizumab) [175,210,211], IL-4Rα (dupilumab) [169,170,171,212], and TSLP (tezepelumab) [188,189] have been demonstrated to reduce annual exacerbation rates and also certain features (e.g., FEV₁) of airway remodeling in severe asthmatic patients. The efficacy and safety of the above mAbs have been recently discussed in detail [142]. Collectively, these clinical findings support the involvement of lung mast cells in central features of severe asthma.

Several promising mast cell-targeted biologics, such as mAbs anti-IL-33 [200] (NTC04570657), anti-ST2 [202], anti-Siglec-8 (NCT03379311; NCT03436797; NCT04322708), and CDX-0159 (NCT04146129) have entered clinical development in asthma or allergic disorders. Moreover, several classes of drugs silencing or depleting mast cells (e.g., TKIs) have shown promising results in patients with severe uncontrolled asthma [262,263,264].

We are going through an exciting and promising era for understanding human mast cell biology. However, we must consider that many aspects of mast cell biology and their complex phenotypic and functional heterogeneity remain largely unknown. Mast cells are exposed to their local environment that, over time, can modify their phenotype and biochemical machinery [277]. More studies using novel techniques (e.g., single-cell mRNA seq, CyTOF) will more accurately reveal mast cell heterogeneity [278,279]. These techniques will contribute to identifying the role of mast cell subtypes in different asthma phenotypes. Another level of complexity derives from the species differences in extrapolating findings from mouse mast cell models to human settings [19,43].

Human mast cells and basophils have some similarities (e.g., FcεRI) but also striking differences [43]. Basophils have been recently identified in the human lung [26,27,280], where they play a prominent role in macrophage differentiation [281]. Macrophages represent the most prominent immune cells in human lung tissue [282,283]. There is also evidence that basophils and their mediators (i.e., IL-4, IL-13) play a role in Th2 and M2 polarization in allergic asthma [43]. Likely, some biologics that primarily target mast cells (e.g., omalizumab, mepolizumab, benralizumab) may also target human basophils [284,285].

Mast cells and their mediators play homeostatic and protective roles in several pathophysiological conditions [19,286]. Moreover, several normal cell types, such as germ cells, hematopoietic stem cells, and melanoblasts, express KIT, and the chronic administration of TKIs and mAbs targeting KIT may be associated with long-term adverse effects. Caution will be necessary in the future when drugs able to markedly reduce tissue mast cells in humans will be available for the treatment of mast cell-driven diseases.

Acknowledgements

The authors apologize to the many researchers who have contributed importantly to this field and whose work was not cited due to space and citation limitations. The authors thank the administrative staff (Roberto Bifulco, Anna Ferraro, and Maria Cristina Fucci) and the medical graphic artist Fabrizio Fiorbianco for the elaboration of figures.

References

1. Ehrlich P.. Beitrage sur Theorie und Praxis der Histologischen Farbung. Ph.D. Thesis. 1878
2. Bradding P., Arthur G.. Mast cells in asthma—State of the art. Clin. Exp. Allergy. 2016;46 194–263. doi:10.1111/cea.12675
3. Galli S.J., Kalesnikoff J., Grimbaldeston M.A., Piliponsky A.M., Williams C.M., Tsai M.. Mast cells as “tunable” effector and immunoregulatory cells: Recent advances. Annu. Rev. Immunol.. 2005;23 749–786. doi:10.1146/annurev.immunol.21.120601.141025
4. Rivellese F., Nerviani A., Rossi F.W., Marone G., Matucci-Cerinic M., de Paulis A., et al.. Mast cells in rheumatoid arthritis: Friends or foes?. Autoimmun. Rev.. 2017;16 557–563. doi:10.1016/j.autrev.2017.04.001
5. Piliponsky A.M., Chen C.C., Grimbaldeston M.A., Burns-Guydish S.M., Hardy J., Kalesnikoff J., et al.. Mast cell-derived TNF can exacerbate mortality during severe bacterial infections in C57BL/6-KitW-sh/W-sh mice. Am. J. Pathol.. 2010;176 926–938. doi:10.2353/ajpath.2010.090342
6. Shi G.P., Bot I., Kovanen P.T.. Mast cells in human and experimental cardiometabolic diseases. Nat. Rev. Cardiol.. 2015;12 643–658. doi:10.1038/nrcardio.2015.117
7. Varricchi G., Marone G., Kovanen P.T.. Cardiac Mast Cells: Underappreciated Immune Cells in Cardiovascular Homeostasis and Disease. Trends Immunol.. 2020;41 734–746. doi:10.1016/j.it.2020.06.006
8. Marone G., Varricchi G., Loffredo S., Galdiero M.R., Rivellese F., de Paulis A.. Are Basophils and Mast Cells Masters in HIV Infection?. Int. Arch. Allergy Immunol.. 2016;171 158–165. doi:10.1159/000452889
9. Varricchi G., Galdiero M.R., Loffredo S., Marone G., Iannone R., Marone G., et al.. Are Mast Cells MASTers in Cancer?. Front. Immunol.. 2017;8 424. doi:10.3389/fimmu.2017.00424
10. Cheng S., Li Z., Gao R., Xing B., Gao Y., Yang Y., et al.. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184 792–809.e23. doi:10.1016/j.cell.2021.01.010
11. Varricchi G., Galdiero M.R., Marone G., Granata F., Borriello F., Marone G.. Controversial role of mast cells in skin cancers. Exp. Dermatol.. 2017;26 11–17. doi:10.1111/exd.13107
12. Dahlin J.S., Ekoff M., Grootens J., Lof L., Amini R.M., Hagberg H., et al.. KIT signaling is dispensable for human mast cell progenitor development. Blood. 2017;130 1785–1794. doi:10.1182/blood-2017-03-773374
13. Marone G., Borriello F., Varricchi G., Genovese A., Granata F.. Basophils: Historical reflections and perspectives. Chem. Immunol. Allergy. 2014;100 172–192. doi:10.1159/000358734
14. Chhiba K.D., Hsu C.L., Berdnikovs S., Bryce P.J.. Transcriptional Heterogeneity of Mast Cells and Basophils upon Activation. J. Immunol.. 2017;198 4868–4878. doi:10.4049/jimmunol.1601825
15. Yamamoto T., Katayama I., Nishioka K.. Expression of stem cell factor in basal cell carcinoma. Br. J. Dermatol.. 1997;137 709–713. doi:10.1111/j.1365-2133.1997.tb01106.x
16. Tsai M., Valent P., Galli S.J.. KIT as a master regulator of the mast cell lineage. J. Allergy Clin. Immunol.. 2022;149 1845–1854. doi:10.1016/j.jaci.2022.04.012
17. Welle M.. Development, significance, and heterogeneity of mast cells with particular regard to the mast cell-specific proteases chymase and tryptase. J. Leukoc. Biol.. 1997;61 233–245. doi:10.1002/jlb.61.3.233
18. Irani A.M., Schwartz L.B.. Human mast cell heterogeneity. Allergy Proc.. 1994;15 303–308. doi:10.2500/108854194778816472
19. Varricchi G., de Paulis A., Marone G., Galli S.J.. Future Needs in Mast Cell Biology. Int. J. Mol. Sci.. 2019;20 doi:10.3390/ijms20184397
20. Derakhshan T., Samuchiwal S.K., Hallen N., Bankova L.G., Boyce J.A., Barrett N.A., et al.. Lineage-specific regulation of inducible and constitutive mast cells in allergic airway inflammation. J. Exp. Med.. 2021;218 e20200321. doi:10.1084/jem.20200321
21. Dwyer D.F., Ordovas-Montanes J., Allon S.J., Buchheit K.M., Vukovic M., Derakhshan T., et al.. Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation. Sci. Immunol.. 2021;6 eabb7221. doi:10.1126/sciimmunol.abb7221
22. Dwyer D.F., Barrett N.A., Austen K.F.. Expression profiling of constitutive mast cells reveals a unique identity within the immune system. Nat. Immunol.. 2016;17 878–887. doi:10.1038/ni.3445
23. Sasaki H., Kurotaki D., Osato N., Sato H., Sasaki I., Koizumi S., et al.. Transcription factor IRF8 plays a critical role in the development of murine basophils and mast cells. Blood. 2015;125 358–369. doi:10.1182/blood-2014-02-557983
24. Motakis E., Guhl S., Ishizu Y., Itoh M., Kawaji H., de Hoon M., et al.. Redefinition of the human mast cell transcriptome by deep-CAGE sequencing. Blood. 2014;123 e58–e67. doi:10.1182/blood-2013-02-483792
25. Plum T., Wang X., Rettel M., Krijgsveld J., Feyerabend T.B., Rodewald H.R.. Human Mast Cell Proteome Reveals Unique Lineage, Putative Functions, and Structural Basis for Cell Ablation. Immunity. 2020;52 404–416.e5. doi:10.1016/j.immuni.2020.01.012
26. Reyfman P.A., Walter J.M., Joshi N., Anekalla K.R., McQuattie-Pimentel A.C., Chiu S., et al.. Single-Cell Transcriptomic Analysis of Human Lung Provides Insights into the Pathobiology of Pulmonary Fibrosis. Am. J. Respir. Crit. Care Med.. 2019;199 1517–1536. doi:10.1164/rccm.201712-2410OC
27. Zilionis R., Engblom C., Pfirschke C., Savova V., Zemmour D., Saatcioglu H.D., et al.. Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species. Immunity. 2019;50 1317–1334.e10. doi:10.1016/j.immuni.2019.03.009
28. Cildir G., Toubia J., Yip K.H., Zhou M., Pant H., Hissaria P., et al.. Genome-wide Analyses of Chromatin State in Human Mast Cells Reveal Molecular Drivers and Mediators of Allergic and Inflammatory Diseases. Immunity. 2019;51 949–965.e6. doi:10.1016/j.immuni.2019.09.021
29. Andersson C.K., Mori M., Bjermer L., Lofdahl C.G., Erjefalt J.S.. Novel site-specific mast cell subpopulations in the human lung. Thorax.. 2009;64 297–305. doi:10.1136/thx.2008.101683
30. Galdiero M.R., Varricchi G., Seaf M., Marone G., Levi-Schaffer F., Marone G.. Bidirectional Mast Cell-Eosinophil Interactions in Inflammatory Disorders and Cancer. Front. Med.. 2017;4 103. doi:10.3389/fmed.2017.00103
31. Poto R., Quinti I., Marone G., Taglialatela M., de Paulis A., Casolaro V., et al.. IgG Autoantibodies Against IgE from Atopic Dermatitis Can Induce the Release of Cytokines and Proinflammatory Mediators from Basophils and Mast Cells. Front. Immunol.. 2022;13 880412. doi:10.3389/fimmu.2022.880412
32. Genovese A., Borgia G., Bjorck L., Petraroli A., de Paulis A., Piazza M., et al.. Immunoglobulin superantigen protein L induces IL-4 and IL-13 secretion from human Fc epsilon RI+ cells through interaction with the kappa light chains of IgE. J. Immunol.. 2003;170 1854–1861. doi:10.4049/jimmunol.170.4.1854
33. Florio G., Petraroli A., Patella V., Triggiani M., Marone G.. The immunoglobulin superantigen-binding site of HIV-1 gp120 activates human basophils. AIDS. 2000;14 931–938. doi:10.1097/00002030-200005260-00004
34. Leist M., Sunder C.A., Drube S., Zimmermann C., Geldmacher A., Metz M., et al.. Membrane-bound stem cell factor is the major but not only driver of fibroblast-induced murine skin mast cell differentiation. Exp. Dermatol.. 2017;26 255–262. doi:10.1111/exd.13206
35. Da Silva C.A., Reber L., Frossard N.. Stem cell factor expression, mast cells and inflammation in asthma. Fundam. Clin. Pharmacol.. 2006;20 21–39. doi:10.1111/j.1472-8206.2005.00390.x
36. Patella V., Marino I., Arbustini E., Lamparter-Schummert B., Verga L., Adt M., et al.. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation. 1998;97 971–978. doi:10.1161/01.CIR.97.10.971
37. de Paulis A., Minopoli G., Arbustini E., de Crescenzo G., Dal Piaz F., Pucci P., et al.. Stem cell factor is localized in, released from, and cleaved by human mast cells. J. Immunol.. 1999;163 2799–2808.
38. Semlali A., Jacques E., Koussih L., Gounni A.S., Chakir J.. Thymic stromal lymphopoietin-induced human asthmatic airway epithelial cell proliferation through an IL-13-dependent pathway. J. Allergy Clin. Immunol.. 2010;125 844–850. doi:10.1016/j.jaci.2010.01.044
39. Leichner T.M., Satake A., Harrison V.S., Tanaka Y., Archambault A.S., Kim B.S., et al.. Skin-derived TSLP systemically expands regulatory T cells. J. Autoimmun.. 2017;79 39–52. doi:10.1016/j.jaut.2017.01.003
40. Varricchi G., Pecoraro A., Marone G., Criscuolo G., Spadaro G., Genovese A., et al.. Thymic Stromal Lymphopoietin Isoforms, Inflammatory Disorders, and Cancer. Front. Immunol.. 2018;9 1595. doi:10.3389/fimmu.2018.01595
41. Siracusa M.C., Saenz S.A., Hill D.A., Kim B.S., Headley M.B., Doering T.A., et al.. TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. Nature. 2011;477 229–233. doi:10.1038/nature10329
42. Allakhverdi Z., Comeau M.R., Jessup H.K., Yoon B.R., Brewer A., Chartier S., et al.. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J. Exp. Med.. 2007;204 253–258. doi:10.1084/jem.20062211
43. Gambardella A.R., Poto R., Tirelli V., Schroeder J.T., Marone G., Mattei F., et al.. Differential Effects of Alarmins on Human and Mouse Basophils. Front. Immunol.. 2022;13 894163. doi:10.3389/fimmu.2022.894163
44. Shikotra A., Ohri C.M., Green R.H., Waller D.A., Bradding P.. Mast cell phenotype, TNFalpha expression and degranulation status in non-small cell lung cancer. Sci. Rep.. 2016;6 38352. doi:10.1038/srep38352
45. Kaur D., Doe C., Woodman L., Heidi Wan W.Y., Sutcliffe A., Hollins F., et al.. Mast cell-airway smooth muscle crosstalk: The role of thymic stromal lymphopoietin. Chest. 2012;142 76–85. doi:10.1378/chest.11-1782
46. Afferni C., Buccione C., Andreone S., Galdiero M.R., Varricchi G., Marone G., et al.. The Pleiotropic Immunomodulatory Functions of IL-33 and Its Implications in Tumor Immunity. Front. Immunol.. 2018;9 2601. doi:10.3389/fimmu.2018.02601
47. Cayrol C., Girard J.P.. Interleukin-33 (IL-33): A nuclear cytokine from the IL-1 family. Immunol. Rev.. 2018;281 154–168. doi:10.1111/imr.12619
48. Hsu C.L., Neilsen C.V., Bryce P.J.. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS ONE. 2010;5 doi:10.1371/journal.pone.0011944
49. Russi A.E., Ebel M.E., Yang Y., Brown M.A.. Male-specific IL-33 expression regulates sex-dimorphic EAE susceptibility. Proc. Natl. Acad. Sci. USA. 2018;115 E1520–E1529. doi:10.1073/pnas.1710401115
50. Iikura M., Suto H., Kajiwara N., Oboki K., Ohno T., Okayama Y., et al.. IL-33 can promote survival, adhesion and cytokine production in human mast cells. Lab. Invest.. 2007;87 971–978. doi:10.1038/labinvest.3700663
51. Bandara G., Beaven M.A., Olivera A., Gilfillan A.M., Metcalfe D.D.. Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33. Eur. J. Immunol.. 2015;45 3034–3044. doi:10.1002/eji.201545501
52. Kaur D., Gomez E., Doe C., Berair R., Woodman L., Saunders R., et al.. IL-33 drives airway hyper-responsiveness through IL-13-mediated mast cell: Airway smooth muscle crosstalk. Allergy. 2015;70 556–567. doi:10.1111/all.12593
53. Silver M.R., Margulis A., Wood N., Goldman S.J., Kasaian M., Chaudhary D.. IL-33 synergizes with IgE-dependent and IgE-independent agents to promote mast cell and basophil activation. Inflamm. Res.. 2010;59 207–218. doi:10.1007/s00011-009-0088-5
54. Joulia R., L’Faqihi F.E., Valitutti S., Espinosa E.. IL-33 fine tunes mast cell degranulation and chemokine production at the single-cell level. J. Allergy Clin. Immunol.. 2017;140 497–509.e10. doi:10.1016/j.jaci.2016.09.049
55. Taracanova A., Alevizos M., Karagkouni A., Weng Z., Norwitz E., Conti P., et al.. SP and IL-33 together markedly enhance TNF synthesis and secretion from human mast cells mediated by the interaction of their receptors. Proc. Natl. Acad. Sci. USA. 2017;114 E4002–E4009. doi:10.1073/pnas.1524845114
56. Theoharides T.C., Zhang B., Kempuraj D., Tagen M., Vasiadi M., Angelidou A., et al.. IL-33 augments substance P-induced VEGF secretion from human mast cells and is increased in psoriatic skin. Proc. Natl. Acad. Sci. USA. 2010;107 4448–4453. doi:10.1073/pnas.1000803107
57. Rivellese F., Suurmond J., Habets K., Dorjee A.L., Ramamoorthi N., Townsend M.J., et al.. Ability of Interleukin-33- and Immune Complex-Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses. Arthritis Rheumatol.. 2015;67 2343–2353. doi:10.1002/art.39192
58. Cristinziano L., Poto R., Criscuolo G., Ferrara A.L., Galdiero M.R., Modestino L., et al.. IL-33 and Superantigenic Activation of Human Lung Mast Cells Induce the Release of Angiogenic and Lymphangiogenic Factors. Cells. 2021;10 doi:10.3390/cells10010145
59. Igawa S., Di Nardo A.. Skin microbiome and mast cells. Transl. Res.. 2017;184 68–76. doi:10.1016/j.trsl.2017.03.003
60. Zhang Y.Y., Yu Y.Y., Zhang Y.R., Zhang W., Yu B.. The modulatory effect of TLR2 on LL-37-induced human mast cells activation. Biochem. Biophys. Res. Commun.. 2016;470 368–374. doi:10.1016/j.bbrc.2016.01.037
61. Kulka M., Alexopoulou L., Flavell R.A., Metcalfe D.D.. Activation of mast cells by double-stranded RNA: Evidence for activation through Toll-like receptor 3. J. Allergy. Clin. Immunol.. 2004;114 174–182. doi:10.1016/j.jaci.2004.03.049
62. Suurmond J., Rivellese F., Dorjee A.L., Bakker A.M., Rombouts Y.J., Rispens T., et al.. Toll-like receptor triggering augments activation of human mast cells by anti-citrullinated protein antibodies. Ann. Rheum. Dis.. 2015;74 1915–1923. doi:10.1136/annrheumdis-2014-205562
63. Suurmond J., Dorjee A.L., Knol E.F., Huizinga T.W., Toes R.E.. Differential TLR-induced cytokine production by human mast cells is amplified by FcvarepsilonRI triggering. Clin. Exp. Allergy. 2015;45 788–796. doi:10.1111/cea.12509
64. Schroeder J.T.. Basophils: Emerging roles in the pathogenesis of allergic disease. Immunol. Rev.. 2011;242 144–160. doi:10.1111/j.1600-065X.2011.01023.x
65. Patella V., Marino I., Lamparter B., Arbustini E., Adt M., Marone G.. Human heart mast cells. Isolation, purification, ultrastructure, and immunologic characterization. J. Immunol.. 1995;154 2855–2865.
66. Hofstra C.L., Desai P.J., Thurmond R.L., Fung-Leung W.P.. Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells. J. Pharmacol. Exp. Ther.. 2003;305 1212–1221. doi:10.1124/jpet.102.046581
67. Triggiani M., Gentile M., Secondo A., Granata F., Oriente A., Taglialatela M., et al.. Histamine induces exocytosis and IL-6 production from human lung macrophages through interaction with H1 receptors. J. Immunol.. 2001;166 4083–4091. doi:10.4049/jimmunol.166.6.4083
68. Levi-Schaffer F., Eliashar R.. Mast cell stabilizing properties of antihistamines. J. Invest. Dermatol.. 2009;129 2549–2551. doi:10.1038/jid.2009.256
69. Genovese A., Patella V., De Crescenzo G., De Paulis A., Spadaro G., Marone G.. Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells. Clin. Exp. Allergy. 1997;27 559–567. doi:10.1111/j.1365-2222.1997.tb00745.x
70. Malbec O., Cassard L., Albanesi M., Jonsson F., Mancardi D., Chicanne G., et al.. Trans-inhibition of activation and proliferation signals by Fc receptors in mast cells and basophils. Sci. Signal. 2016;9 ra126. doi:10.1126/scisignal.aag1401
71. Levi-Schaffer F., Gibbs B.F., Hallgren J., Pucillo C., Redegeld F., Siebenhaar F., et al.. Selected recent advances in understanding the role of human mast cells in health and disease. J. Allergy Clin. Immunol.. 2022;149 1833–1844. doi:10.1016/j.jaci.2022.01.030
72. Gibbs B.F., Sabato V., Bridts C.H., Ebo D.G., Ben-Zimra M., Levi-Schaffer F.. Expressions and inhibitory functions of CD300a receptors on purified human basophils. Exp. Dermatol.. 2012;21 884–886. doi:10.1111/exd.12018
73. Sabato V., Verweij M.M., Bridts C.H., Levi-Schaffer F., Gibbs B.F., De Clerck L.S., et al.. CD300a is expressed on human basophils and seems to inhibit IgE/FcepsilonRI-dependent anaphylactic degranulation. Cytom. B Clin. Cytom.. 2012;82 132–138. doi:10.1002/cyto.b.21003
74. Bachelet I., Munitz A., Moretta A., Moretta L., Levi-Schaffer F.. The inhibitory receptor IRp60 (CD300a) is expressed and functional on human mast cells. J. Immunol.. 2005;175 7989–7995. doi:10.4049/jimmunol.175.12.7989
75. Bachelet I., Munitz A., Levi-Schaffer F.. Abrogation of allergic reactions by a bispecific antibody fragment linking IgE to CD300a. J. Allergy Clin. Immunol.. 2006;117 1314–1320. doi:10.1016/j.jaci.2006.04.031
76. Robida P.A., Rische C.H., Morgenstern N.B., Janarthanam R., Cao Y., Krier-Burris R.A., et al.. Functional and Phenotypic Characterization of Siglec-6 on Human Mast Cells. Cells. 2022;11 doi:10.3390/cells11071138
77. Hudson S.A., Herrmann H., Du J., Cox P., Haddadel B., Butler B., et al.. Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression. J. Clin. Immunol.. 2011;31 1045–1053. doi:10.1007/s10875-011-9589-4
78. Mizrahi S., Gibbs B.F., Karra L., Ben-Zimra M., Levi-Schaffer F.. Siglec-7 is an inhibitory receptor on human mast cells and basophils. J. Allergy Clin. Immunol.. 2014;134 230–233. doi:10.1016/j.jaci.2014.03.031
79. Yokoi H., Myers A., Matsumoto K., Crocker P.R., Saito H., Bochner B.S.. Alteration and acquisition of Siglecs during in vitro maturation of CD34+ progenitors into human mast cells. Allergy. 2006;61 769–776. doi:10.1111/j.1398-9995.2006.01133.x
80. Korver W., Wong A., Gebremeskel S., Negri G.L., Schanin J., Chang K., et al.. The Inhibitory Receptor Siglec-8 Interacts With FcepsilonRI and Globally Inhibits Intracellular Signaling in Primary Mast Cells Upon Activation. Front. Immunol.. 2022;13 833728. doi:10.3389/fimmu.2022.833728
81. Kikly K.K., Bochner B.S., Freeman S.D., Tan K.B., Gallagher K.T., D’Alessio K.J., et al.. Identification of SAF-2, a novel siglec expressed on eosinophils, mast cells, and basophils. J. Allergy Clin. Immunol.. 2000;105 1093–1100. doi:10.1067/mai.2000.107127
82. Kiwamoto T., Kawasaki N., Paulson J.C., Bochner B.S.. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol. Ther. 2012;135 327–336. doi:10.1016/j.pharmthera.2012.06.005
83. Okayama Y., Kirshenbaum A.S., Metcalfe D.D.. Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: Up-regulation by IFN-gamma. J. Immunol.. 2000;164 4332–4339. doi:10.4049/jimmunol.164.8.4332
84. Zhu D., Kepley C.L., Zhang M., Zhang K., Saxon A.. A novel human immunoglobulin Fc gamma Fc epsilon bifunctional fusion protein inhibits Fc epsilon RI-mediated degranulation. Nat. Med.. 2002;8 518–521. doi:10.1038/nm0502-518
85. Zhu D., Kepley C.L., Zhang K., Terada T., Yamada T., Saxon A.. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat. Med.. 2005;11 446–449. doi:10.1038/nm1219
86. Zhang K., Kepley C.L., Terada T., Zhu D., Perez H., Saxon A.. Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein. J. Allergy Clin. Immunol.. 2004;114 321–327. doi:10.1016/j.jaci.2004.03.058
87. Cemerski S., Chu S.Y., Moore G.L., Muchhal U.S., Desjarlais J.R., Szymkowski D.E.. Suppression of mast cell degranulation through a dual-targeting tandem IgE-IgG Fc domain biologic engineered to bind with high affinity to FcgammaRIIb. Immunol. Lett.. 2012;143 34–43. doi:10.1016/j.imlet.2012.01.008
88. Varricchi G., Raap U., Rivellese F., Marone G., Gibbs B.F.. Human mast cells and basophils-How are they similar how are they different?. Immunol. Rev.. 2018;282 8–34. doi:10.1111/imr.12627
89. Harvima I.T., Nilsson G.. Mast cells as regulators of skin inflammation and immunity. Acta Derm. Venereol.. 2011;91 644–650. doi:10.2340/00015555-1197
90. Brightling C.E., Bradding P., Symon F.A., Holgate S.T., Wardlaw A.J., Pavord I.D.. Mast-cell infiltration of airway smooth muscle in asthma. N. Engl. J. Med.. 2002;346 1699–1705. doi:10.1056/NEJMoa012705
91. Kaur D., Saunders R., Hollins F., Woodman L., Doe C., Siddiqui S., et al.. Mast cell fibroblastoid differentiation mediated by airway smooth muscle in asthma. J. Immunol.. 2010;185 6105–6114. doi:10.4049/jimmunol.1000638
92. Maun H.R., Jackman J.K., Choy D.F., Loyet K.M., Staton T.L., Jia G., et al.. An Allosteric Anti-tryptase Antibody for the Treatment of Mast Cell-Mediated Severe Asthma. Cell. 2019;179 417–431.e19. doi:10.1016/j.cell.2019.09.009
93. Caughey G.H.. Mast cell proteases as pharmacological targets. Eur. J. Pharmacol.. 2016;778 44–55. doi:10.1016/j.ejphar.2015.04.045
94. Huttunen M., Harvima I.T.. Mast cell tryptase and chymase in chronic leg ulcers: Chymase is potentially destructive to epithelium and is controlled by proteinase inhibitors. Br. J. Dermatol.. 2005;152 1149–1160. doi:10.1111/j.1365-2133.2005.06428.x
95. Irani A.M., Goldstein S.M., Wintroub B.U., Bradford T., Schwartz L.B.. Human mast cell carboxypeptidase. Selective localization to MCTC cells. J. Immunol.. 1991;147 247–253.
96. Strik M.C., de Koning P.J., Kleijmeer M.J., Bladergroen B.A., Wolbink A.M., Griffith J.M., et al.. Human mast cells produce and release the cytotoxic lymphocyte associated protease granzyme B upon activation. Mol. Immunol.. 2007;44 3462–3472. doi:10.1016/j.molimm.2007.03.024
97. Di Girolamo N., Indoh I., Jackson N., Wakefield D., McNeil H.P., Yan W., et al.. Human mast cell-derived gelatinase B (matrix metalloproteinase-9) is regulated by inflammatory cytokines: Role in cell migration. J. Immunol.. 2006;177 2638–2650. doi:10.4049/jimmunol.177.4.2638
98. MacGlashan D.W., Peters S.P., Warner J., Lichtenstein L.M.. Characteristics of human basophil sulfidopeptide leukotriene release: Releasability defined as the ability of the basophil to respond to dimeric cross-links. J. Immunol.. 1986;136 2231–2239.
99. Austen K.F.. The cysteinyl leukotrienes: Where do they come from? What are they? Where are they going?. Nat. Immunol.. 2008;9 113–115. doi:10.1038/ni0208-113
100. Dahlen S.E., Kumlin M.. Monitoring mast cell activation by prostaglandin D2 in vivo. Thorax. 2004;59 453–455. doi:10.1136/thx.2004.026641
101. Schuligoi R., Sturm E., Luschnig P., Konya V., Philipose S., Sedej M., et al.. CRTH2 and D-type prostanoid receptor antagonists as novel therapeutic agents for inflammatory diseases. Pharmacology. 2010;85 372–382. doi:10.1159/000313836
102. Triggiani M., Hubbard W.C., Chilton F.H.. Synthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine by an enriched preparation of the human lung mast cell. J. Immunol.. 1990;144 4773–4780.
103. Ohkawara Y., Yamauchi K., Tanno Y., Tamura G., Ohtani H., Nagura H., et al.. Human lung mast cells and pulmonary macrophages produce tumor necrosis factor-alpha in sensitized lung tissue after IgE receptor triggering. Am. J. Respir. Cell Mol. Biol.. 1992;7 385–392. doi:10.1165/ajrcmb/7.4.385
104. Okayama Y., Hagaman D.D., Metcalfe D.D.. A comparison of mediators released or generated by IFN-gamma-treated human mast cells following aggregation of Fc gamma RI or Fc epsilon RI. J. Immunol.. 2001;166 4705–4712. doi:10.4049/jimmunol.166.7.4705
105. Nouri-Aria K.T., Pilette C., Jacobson M.R., Watanabe H., Durham S.R.. IL-9 and c-Kit+ mast cells in allergic rhinitis during seasonal allergen exposure: Effect of immunotherapy. J. Allergy Clin. Immunol.. 2005;116 73–79. doi:10.1016/j.jaci.2005.03.011
106. Ishizuka T., Okayama Y., Kobayashi H., Mori M.. Interleukin-3 production by mast cells from human lung. Inflammation. 1999;23 25–35. doi:10.1023/A:1020235400073
107. Okayama Y., Petit-Frere C., Kassel O., Semper A., Quint D., Tunon-de-Lara M.J., et al.. IgE-dependent expression of mRNA for IL-4 and IL-5 in human lung mast cells. J. Immunol.. 1995;155 1796–1808.
108. Suttle M.M., Nilsson G., Snellman E., Harvima I.T.. Experimentally induced psoriatic lesion associates with interleukin (IL)-6 in mast cells and appearance of dermal cells expressing IL-33 and IL-6 receptor. Clin. Exp. Immunol.. 2012;169 311–319. doi:10.1111/j.1365-2249.2012.04618.x
109. Lorentz A., Schwengberg S., Sellge G., Manns M.P., Bischoff S.C.. Human intestinal mast cells are capable of producing different cytokine profiles: Role of IgE receptor cross-linking and IL-4. J. Immunol.. 2000;164 43–48. doi:10.4049/jimmunol.164.1.43
110. Burd P.R., Thompson W.C., Max E.E., Mills F.C.. Activated mast cells produce interleukin 13. J. Exp. Med.. 1995;181 1373–1380. doi:10.1084/jem.181.4.1373
111. Rumsaeng V., Cruikshank W.W., Foster B., Prussin C., Kirshenbaum A.S., Davis T.A., et al.. Human mast cells produce the CD4+ T lymphocyte chemoattractant factor, IL-16. J. Immunol.. 1997;159 2904–2910.
112. Mashiko S., Bouguermouh S., Rubio M., Baba N., Bissonnette R., Sarfati M.. Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis. J. Allergy Clin. Immunol.. 2015;136 351–359.e1. doi:10.1016/j.jaci.2015.01.033
113. Okayama Y., Okumura S., Sagara H., Yuki K., Sasaki T., Watanabe N., et al.. FcepsilonRI-mediated thymic stromal lymphopoietin production by interleukin-4-primed human mast cells. Eur. Respir. J.. 2009;34 425–435. doi:10.1183/09031936.00121008
114. Ying S., O’Connor B., Ratoff J., Meng Q., Mallett K., Cousins D., et al.. Thymic stromal lymphopoietin expression is increased in asthmatic airways and correlates with expression of Th2-attracting chemokines and disease severity. J. Immunol.. 2005;174 8183–8190. doi:10.4049/jimmunol.174.12.8183
115. Shikotra A., Choy D.F., Ohri C.M., Doran E., Butler C., Hargadon B., et al.. Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. J. Allergy Clin. Immunol.. 2012;129 104–111.e1-9. doi:10.1016/j.jaci.2011.08.031
116. Shin H.W., Kim D.K., Park M.H., Eun K.M., Lee M., So D., et al.. IL-25 as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis. J. Allergy Clin. Immunol.. 2015;135 1476–1485.e7. doi:10.1016/j.jaci.2015.01.003
117. Detoraki A., Staiano R.I., Granata F., Giannattasio G., Prevete N., de Paulis A., et al.. Vascular endothelial growth factors synthesized by human lung mast cells exert angiogenic effects. J. Allergy Clin. Immunol.. 2009;123 1142–1149.e1-5. doi:10.1016/j.jaci.2009.01.044
118. Dvorak A.M., Morgan E.S., Weller P.F.. Ultrastructural immunolocalization of basic fibroblast growth factor to lipid bodies and secretory granules in human mast cells. Histochem. J.. 2001;33 397–402. doi:10.1023/A:1013771827069
119. Nilsson G., Forsberg-Nilsson K., Xiang Z., Hallbook F., Nilsson K., Metcalfe D.D.. Human mast cells express functional TrkA and are a source of nerve growth factor. Eur. J. Immunol.. 1997;27 2295–2301. doi:10.1002/eji.1830270925
120. Okumura S., Sagara H., Fukuda T., Saito H., Okayama Y.. FcepsilonRI-mediated amphiregulin production by human mast cells increases mucin gene expression in epithelial cells. J. Allergy Clin. Immunol.. 2005;115 272–279. doi:10.1016/j.jaci.2004.10.004
121. Wang S.W., Oh C.K., Cho S.H., Hu G., Martin R., Demissie-Sanders S., et al.. Amphiregulin expression in human mast cells and its effect on the primary human lung fibroblasts. J. Allergy Clin. Immunol.. 2005;115 287–294. doi:10.1016/j.jaci.2004.11.037
122. Yano K., Yamaguchi M., de Mora F., Lantz C.S., Butterfield J.H., Costa J.J., et al.. Production of macrophage inflammatory protein-1alpha by human mast cells: Increased anti-IgE-dependent secretion after IgE-dependent enhancement of mast cell IgE-binding ability. Lab. Invest.. 1997;77 185–193.
123. Melillo R.M., Guarino V., Avilla E., Galdiero M.R., Liotti F., Prevete N., et al.. Mast cells have a protumorigenic role in human thyroid cancer. Oncogene. 2010;29 6203–6215. doi:10.1038/onc.2010.348
124. Visciano C., Liotti F., Prevete N., Cali G., Franco R., Collina F., et al.. Mast cells induce epithelial-to-mesenchymal transition and stem cell features in human thyroid cancer cells through an IL-8-Akt-Slug pathway. Oncogene. 2015;34 5175–5186. doi:10.1038/onc.2014.441
125. Granata F., Frattini A., Loffredo S., Staiano R.I., Petraroli A., Ribatti D., et al.. Production of vascular endothelial growth factors from human lung macrophages induced by group IIA and group X secreted phospholipases A2. J. Immunol.. 2010;184 5232–5241. doi:10.4049/jimmunol.0902501
126. de Paulis A., Prevete N., Fiorentino I., Rossi F.W., Staibano S., Montuori N., et al.. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J. Immunol.. 2006;177 7322–7331. doi:10.4049/jimmunol.177.10.7322
127. Loffredo S., Borriello F., Iannone R., Ferrara A.L., Galdiero M.R., Gigantino V., et al.. Group V Secreted Phospholipase A2 Induces the Release of Proangiogenic and Antiangiogenic Factors by Human Neutrophils. Front. Immunol.. 2017;8 443. doi:10.3389/fimmu.2017.00443
128. Poto R., Cristinziano L., Modestino L., de Paulis A., Marone G., Loffredo S., et al.. Neutrophil Extracellular Traps, Angiogenesis and Cancer. Biomedicines. 2022;10 doi:10.3390/biomedicines10020431
129. Thomas M., Augustin H.G.. The role of the Angiopoietins in vascular morphogenesis. Angiogenesis. 2009;12 125–137. doi:10.1007/s10456-009-9147-3
130. Loffredo S., Bova M., Suffritti C., Borriello F., Zanichelli A., Petraroli A., et al.. Elevated plasma levels of vascular permeability factors in C1 inhibitor-deficient hereditary angioedema. Allergy. 2016;71 989–996. doi:10.1111/all.12862
131. Varricchi G., Loffredo S., Bencivenga L., Ferrara A.L., Gambino G., Ferrara N., et al.. Angiopoietins, Vascular Endothelial Growth Factors and Secretory Phospholipase A2 in Ischemic and Non-Ischemic Heart Failure. J. Clin. Med.. 2020;9 doi:10.3390/jcm9061928
132. Varricchi G., Poto R., Ferrara A.L., Gambino G., Marone G., Rengo G., et al.. Angiopoietins, vascular endothelial growth factors and secretory phospholipase A2 in heart failure patients with preserved ejection fraction. Eur. J. Intern. Med.. 2022;22 S0953. doi:10.1016/j.ejim.2022.10.014
133. Duah E., Teegala L.R., Kondeti V., Adapala R.K., Keshamouni V.G., Kanaoka Y., et al.. Cysteinyl leukotriene 2 receptor promotes endothelial permeability, tumor angiogenesis, and metastasis. Proc. Natl. Acad. Sci. USA. 2019;116 199–204. doi:10.1073/pnas.1817325115
134. Patella V., Florio G., Petraroli A., Marone G.. HIV-1 gp120 induces IL-4 and IL-13 release from human Fc epsilon RI+ cells through interaction with the VH3 region of IgE. J. Immunol.. 2000;164 589–595. doi:10.4049/jimmunol.164.2.589
135. Yang W., Kaur D., Okayama Y., Ito A., Wardlaw A.J., Brightling C.E., et al.. Human lung mast cells adhere to human airway smooth muscle, in part, via tumor suppressor in lung cancer-1. J. Immunol.. 2006;176 1238–1243. doi:10.4049/jimmunol.176.2.1238
136. Hollins F., Kaur D., Yang W., Cruse G., Saunders R., Sutcliffe A., et al.. Human airway smooth muscle promotes human lung mast cell survival, proliferation, and constitutive activation: Cooperative roles for CADM1, stem cell factor, and IL-6. J. Immunol.. 2008;181 2772–2780. doi:10.4049/jimmunol.181.4.2772
137. Salomonsson M., Malinovschi A., Kalm-Stephens P., Dahlin J.S., Janson C., Alving K., et al.. Circulating mast cell progenitors correlate with reduced lung function in allergic asthma. Clin. Exp. Allergy. 2019;49 874–882. doi:10.1111/cea.13388
138. Schleimer R.P., MacGlashan D.W., Peters S.P., Pinckard R.N., Adkinson N.F., Lichtenstein L.M.. Characterization of inflammatory mediator release from purified human lung mast cells. Am. Rev. Respir. Dis.. 1986;133 614–617. doi:10.1164/arrd.1986.133.4.614
139. Murray J.J., Tonnel A.B., Brash A.R., Roberts L.J., Gosset P., Workman R., et al.. Release of prostaglandin D2 into human airways during acute antigen challenge. N. Engl. J. Med.. 1986;315 800–804. doi:10.1056/NEJM198609253151304
140. Casale T.B., Wood D., Richerson H.B., Zehr B., Zavala D., Hunninghake G.W.. Direct evidence of a role for mast cells in the pathogenesis of antigen-induced bronchoconstriction. J. Clin. Invest.. 1987;80 1507–1511. doi:10.1172/JCI113234
141. Wenzel S.E., Fowler A.A., Schwartz L.B.. Activation of pulmonary mast cells by bronchoalveolar allergen challenge. In vivo release of histamine and tryptase in atopic subjects with and without asthma. Am. Rev. Respir. Dis.. 1988;137 1002–1008. doi:10.1164/ajrccm/137.5.1002
142. Varricchi G., Ferri S., Pepys J., Poto R., Spadaro G., Nappi E., et al.. Biologics and airway remodeling in severe asthma. Allergy. 2022 doi:10.1111/all.15473
143. Hoshino M., Takahashi M., Aoike N.. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J. Allergy. Clin. Immunol.. 2001;107 295–301. doi:10.1067/mai.2001.111928
144. Chetta A., Zanini A., Foresi A., Del Donno M., Castagnaro A., D’Ippolito R., et al.. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am. J. Respir. Crit. Care Med.. 2003;167 751–757. doi:10.1164/rccm.200207-710OC
145. Detoraki A., Granata F., Staibano S., Rossi F.W., Marone G., Genovese A.. Angiogenesis and lymphangiogenesis in bronchial asthma. Allergy. 2010;65 946–958. doi:10.1111/j.1398-9995.2010.02372.x
146. Varricchi G., Loffredo S., Borriello F., Pecoraro A., Rivellese F., Genovese A., et al.. Superantigenic Activation of Human Cardiac Mast Cells. Int. J. Mol. Sci.. 2019;20 doi:10.3390/ijms20081828
147. Altman M.C., Lai Y., Nolin J.D., Long S., Chen C.C., Piliponsky A.M., et al.. Airway epithelium-shifted mast cell infiltration regulates asthmatic inflammation via IL-33 signaling. J. Clin. Invest.. 2019;129 4979–4991. doi:10.1172/JCI126402
148. Theoharides T.C., Spanos C., Pang X., Alferes L., Ligris K., Letourneau R., et al.. Stress-induced intracranial mast cell degranulation: A corticotropin-releasing hormone-mediated effect. Endocrinology. 1995;136 5745–5750. doi:10.1210/endo.136.12.7588332
149. Cao J., Cetrulo C.L., Theoharides T.C.. Corticotropin-releasing hormone induces vascular endothelial growth factor release from human mast cells via the cAMP/protein kinase A/p38 mitogen-activated protein kinase pathway. Mol. Pharmacol.. 2006;69 998–1006. doi:10.1124/mol.105.019539
150. Theoharides T.C., Enakuaa S., Sismanopoulos N., Asadi S., Papadimas E.C., Angelidou A., et al.. Contribution of stress to asthma worsening through mast cell activation. Ann. Allergy Asthma Immunol.. 2012;109 14–19. doi:10.1016/j.anai.2012.03.003
151. Varricchi G., Rossi F.W., Galdiero M.R., Granata F., Criscuolo G., Spadaro G., et al.. Physiological Roles of Mast Cells: Collegium Internationale Allergologicum Update 2019. Int. Arch. Allergy Immunol.. 2019;179 247–261. doi:10.1159/000500088
152. Zuberbier T., Aberer W., Asero R., Abdul Latiff A.H., Baker D., Ballmer-Weber B., et al.. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73 1393–1414. doi:10.1111/all.13397
153. Bousquet J., Schunemann H.J., Togias A., Bachert C., Erhola M., Hellings P.W., et al.. Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. J. Allergy Clin. Immunol.. 2020;145 70–80.e3. doi:10.1016/j.jaci.2019.06.049
154. Kay L.J., Suvarna S.K., Peachell P.T.. Histamine H4 receptor mediates chemotaxis of human lung mast cells. Eur. J. Pharmacol.. 2018;837 38–44. doi:10.1016/j.ejphar.2018.08.028
155. Murata Y., Song M., Kikuchi H., Hisamichi K., Xu X.L., Greenspan A., et al.. Phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study of a H4 R-antagonist (JNJ-39758979) in Japanese adults with moderate atopic dermatitis. J. Dermatol.. 2015;42 129–139. doi:10.1111/1346-8138.12726
156. Kollmeier A.P., Barnathan E.S., O’Brien C., Chen B., Xia Y.K., Zhou B., et al.. A phase 2a study of toreforant, a histamine H4 receptor antagonist, in eosinophilic asthma. Ann. Allergy Asthma. Immunol.. 2018;121 568–574. doi:10.1016/j.anai.2018.08.001
157. Werfel T., Layton G., Yeadon M., Whitlock L., Osterloh I., Jimenez P., et al.. Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis. J. Allergy Clin. Immunol.. 2019;143 1830–1837. doi:10.1016/j.jaci.2018.07.047
158. Maun H.R., Vij R., Walters B.T., Morando A., Jackman J.K., Wu P., et al.. Bivalent antibody pliers inhibit beta-tryptase by an allosteric mechanism dependent on the IgG hinge. Nat. Commun.. 2020;11 6435. doi:10.1038/s41467-020-20143-x
159. Marone G., Galdiero M.R., Pecoraro A., Pucino V., Criscuolo G., Triassi M., et al.. Prostaglandin D2 receptor antagonists in allergic disorders: Safety, efficacy, and future perspectives. Expert. Opin. Investig. Drugs. 2019;28 73–84. doi:10.1080/13543784.2019.1555237
160. Brightling C.E., Gaga M., Inoue H., Li J., Maspero J., Wenzel S., et al.. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): Two phase 3 randomised controlled trials. Lancet Respir. Med.. 2021;9 43–56. doi:10.1016/S2213-2600(20)30412-4
161. Asano K., Sagara H., Ichinose M., Hirata M., Nakajima A., Ortega H., et al.. A Phase 2a Study of DP2 Antagonist GB001 for Asthma. J. Allergy Clin. Immunol. Pract.. 2020;8 1275–1283.e1. doi:10.1016/j.jaip.2019.11.016
162. American Lung Association Asthma Clinical Research C., Peters S.P., Anthonisen N., Castro M., Holbrook J.T., Irvin C.G., et al.. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N. Engl. J. Med.. 2007;356 2027–2039. doi:10.1056/NEJMoa070013
163. Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A., et al.. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part II. J. Eur. Acad. Dermatol. Venereol.. 2018;32 850–878. doi:10.1111/jdv.14888
164. Hanania N.A., Korenblat P., Chapman K.R., Bateman E.D., Kopecky P., Paggiaro P., et al.. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): Replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med.. 2016;4 781–796. doi:10.1016/S2213-2600(16)30265-X
165. Panettieri R.A., Sjobring U., Peterffy A., Wessman P., Bowen K., Piper E., et al.. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): Two randomised, double-blind, placebo-controlled, phase 3 clinical trials. Lancet Respir. Med.. 2018;6 511–525. doi:10.1016/S2213-2600(18)30184-X
166. Brightling C.E., Chanez P., Leigh R., O’Byrne P.M., Korn S., She D., et al.. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: A randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir. Med.. 2015;3 692–701. doi:10.1016/S2213-2600(15)00197-6
167. Corren J., Lemanske R.F., Hanania N.A., Korenblat P.E., Parsey M.V., Arron J.R., et al.. Lebrikizumab treatment in adults with asthma. N. Engl. J. Med.. 2011;365 1088–1098. doi:10.1056/NEJMoa1106469
168. Marone G., Granata F., Pucino V., Pecoraro A., Heffler E., Loffredo S., et al.. The Intriguing Role of Interleukin 13 in the Pathophysiology of Asthma. Front. Pharmacol.. 2019;10 1387. doi:10.3389/fphar.2019.01387
169. Wenzel S., Ford L., Pearlman D., Spector S., Sher L., Skobieranda F., et al.. Dupilumab in persistent asthma with elevated eosinophil levels. N. Engl. J. Med.. 2013;368 2455–2466. doi:10.1056/NEJMoa1304048
170. Wenzel S., Castro M., Corren J., Maspero J., Wang L., Zhang B., et al.. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: A randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388 31–44. doi:10.1016/S0140-6736(16)30307-5
171. Castro M., Corren J., Pavord I.D., Maspero J., Wenzel S., Rabe K.F., et al.. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N. Engl. J. Med.. 2018;378 2486–2496. doi:10.1056/NEJMoa1804092
172. Ortega H.G., Liu M.C., Pavord I.D., Brusselle G.G., FitzGerald J.M., Chetta A., et al.. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med.. 2014;371 1198–1207. doi:10.1056/NEJMoa1403290
173. Detoraki A., Tremante E., D’Amato M., Calabrese C., Casella C., Maniscalco M., et al.. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: A 12-month real-life study. Ther. Adv. Respir. Dis.. 2021;15 17534666211009398. doi:10.1177/17534666211009398
174. Castro M., Zangrilli J., Wechsler M.E., Bateman E.D., Brusselle G.G., Bardin P., et al.. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir. Med.. 2015;3 355–366. doi:10.1016/S2213-2600(15)00042-9
175. Harrison T.W., Chanez P., Menzella F., Canonica G.W., Louis R., Cosio B.G., et al.. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): A randomised, controlled, phase 3b trial. Lancet Respir. Med.. 2021;9 260–274. doi:10.1016/S2213-2600(20)30414-8
176. Global Strategy for Asthma Management and Prevention. 2021
177. Castro M., Wenzel S.E., Bleecker E.R., Pizzichini E., Kuna P., Busse W.W., et al.. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: A phase 2b randomised dose-ranging study. Lancet Respir. Med.. 2014;2 879–890. doi:10.1016/S2213-2600(14)70201-2
178. Haldar P., Brightling C.E., Hargadon B., Gupta S., Monteiro W., Sousa A., et al.. Mepolizumab and exacerbations of refractory eosinophilic asthma. N. Engl. J. Med.. 2009;360 973–984. doi:10.1056/NEJMoa0808991
179. Wenzel S.E., Barnes P.J., Bleecker E.R., Bousquet J., Busse W., Dahlen S.E., et al.. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am. J. Respir. Crit. Care Med.. 2009;179 549–558. doi:10.1164/rccm.200809-1512OC
180. Busse W.W., Holgate S., Kerwin E., Chon Y., Feng J., Lin J., et al.. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am. J. Respir. Crit. Care Med.. 2013;188 1294–1302. doi:10.1164/rccm.201212-2318OC
181. Hobo A., Harada K., Maeda T., Uchiyama M., Irisawa R., Yamazaki M., et al.. IL-17-positive mast cell infiltration in the lesional skin of lichen planopilaris: Possible role of mast cells in inducing inflammation and dermal fibrosis in cicatricial alopecia. Exp. Dermatol.. 2020;29 273–277. doi:10.1111/exd.13816
182. Brightling C.E., Nair P., Cousins D.J., Louis R., Singh D.. Risankizumab in Severe Asthma—A Phase 2a, Placebo-Controlled Trial. N. Engl. J. Med.. 2021;385 1669–1679. doi:10.1056/NEJMoa2030880
183. Whetstone C.E., Ranjbar M., Omer H., Cusack R.P., Gauvreau G.M.. The Role of Airway Epithelial Cell Alarmins in Asthma. Cells. 2022;11 doi:10.3390/cells11071105
184. Ebina-Shibuya R., Leonard W.J.. Role of thymic stromal lymphopoietin in allergy and beyond. Nat. Rev. Immunol.. 2022;1 1–14. doi:10.1038/s41577-022-00735-y
185. Marone G., Spadaro G., Braile M., Poto R., Criscuolo G., Pahima H., et al.. Tezepelumab: A novel biological therapy for the treatment of severe uncontrolled asthma. Expert. Opin. Investig. Drugs. 2019;28 931–940. doi:10.1080/13543784.2019.1672657
186. Li Y., Wang W., Lv Z., Li Y., Chen Y., Huang K., et al.. Elevated Expression of IL-33 and TSLP in the Airways of Human Asthmatics In Vivo: A Potential Biomarker of Severe Refractory Disease. J. Immunol.. 2018;200 2253–2262. doi:10.4049/jimmunol.1701455
187. Ko H.K., Cheng S.L., Lin C.H., Lin S.H., Hsiao Y.H., Su K.C., et al.. Blood tryptase and thymic stromal lymphopoietin levels predict the risk of exacerbation in severe asthma. Sci. Rep.. 2021;11 8425. doi:10.1038/s41598-021-86179-1
188. Corren J., Parnes J.R., Wang L., Mo M., Roseti S.L., Griffiths J.M., et al.. Tezepelumab in Adults with Uncontrolled Asthma. N. Engl. J. Med.. 2017;377 936–946. doi:10.1056/NEJMoa1704064
189. Menzies-Gow A., Corren J., Bourdin A., Chupp G., Israel E., Wechsler M.E., et al.. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. N. Engl. J. Med.. 2021;384 1800–1809. doi:10.1056/NEJMoa2034975
190. Diver S., Khalfaoui L., Emson C., Wenzel S.E., Menzies-Gow A., Wechsler M.E., et al.. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): A double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir. Med.. 2021;9 1299–1312. doi:10.1016/S2213-2600(21)00226-5
191. Sverrild A., Hansen S., Hvidtfeldt M., Clausson C.M., Cozzolino O., Cerps S., et al.. The effect of tezepelumab on airway hyperresponsiveness to mannitol in asthma (UPSTREAM). Eur. Respir. J.. 2022;59 2101296. doi:10.1183/13993003.01296-2021
192. Cao L., Liu F., Liu Y., Liu T., Wu J., Zhao J., et al.. TSLP promotes asthmatic airway remodeling via p38-STAT3 signaling pathway in human lung fibroblast. Exp. Lung. Res.. 2018;44 288–301. doi:10.1080/01902148.2018.1536175
193. Braile M., Fiorelli A., Sorriento D., Di Crescenzo R.M., Galdiero M.R., Marone G., et al.. Human Lung-Resident Macrophages Express and Are Targets of Thymic Stromal Lymphopoietin in the Tumor Microenvironment. Cells. 2021;10 doi:10.3390/cells10082012
194. Harbour BioMed Announces First Subject Dosed in Phase I Study of Next-Gen Anti-TSLP Fully Human Monoclonal Antibody. 2022
195. Gauvreau G.M., Hohlfeld J., Boulet L.-P., Cockcroft D., Davis B., FitzGerald J.M., et al.. Late Breaking Abstract—Efficacy of CSJ117 on allergen-induced asthmatic responses in mild atopic asthma patients. Eur. Respir. J.. 2020;56 3690.
196. Wang W., Li Y., Lv Z., Chen Y., Li Y., Huang K., et al.. Bronchial Allergen Challenge of Patients with Atopic Asthma Triggers an Alarmin (IL-33, TSLP, and IL-25) Response in the Airways Epithelium and Submucosa. J. Immunol.. 2018;201 2221–2231. doi:10.4049/jimmunol.1800709
197. Gasiuniene E., Janulaityte I., Zemeckiene Z., Barkauskiene D., Sitkauskiene B.. Elevated levels of interleukin-33 are associated with allergic and eosinophilic asthma. Scand. J. Immunol.. 2019;89 e12724. doi:10.1111/sji.12724
198. Corrigan C.J., Wang W., Meng Q., Fang C., Eid G., Caballero M.R., et al.. Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses. J. Allergy Clin. Immunol.. 2011;128 116–124. doi:10.1016/j.jaci.2011.03.043
199. Beale J., Jayaraman A., Jackson D.J., Macintyre J.D.R., Edwards M.R., Walton R.P., et al.. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci. Transl. Med.. 2014;6 256ra134. doi:10.1126/scitranslmed.3009124
200. Wechsler M.E., Ruddy M.K., Pavord I.D., Israel E., Rabe K.F., Ford L.B., et al.. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. N. Engl. J. Med.. 2021;385 1656–1668. doi:10.1056/NEJMoa2024257
201. Chinthrajah S., Cao S., Liu C., Lyu S.C., Sindher S.B., Long A., et al.. Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy. JCI Insight. 2019;4 e131347. doi:10.1172/jci.insight.131347
202. Kelsen S.G., Agache I.O., Soong W., Israel E., Chupp G.L., Cheung D.S., et al.. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. J. Allergy Clin. Immunol.. 2021;148 790–798. doi:10.1016/j.jaci.2021.03.044
203. Bagnasco D., Ferrando M., Varricchi G., Puggioni F., Passalacqua G., Canonica G.W.. Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. Front. Med.. 2017;4 135. doi:10.3389/fmed.2017.00135
204. Ortega H., Liu M.C., Pavord I.D.. Mepolizumab treatment in patients with severe eosinophilic asthma. N. Engl. J. Med. 2015;372 1777. doi:10.1056/NEJMoa1403290
205. Pavord I.D., Korn S., Howarth P., Bleecker E.R., Buhl R., Keene O.N., et al.. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380 651–659. doi:10.1016/S0140-6736(12)60988-X
206. Chupp G.L., Bradford E.S., Albers F.C., Bratton D.J., Wang-Jairaj J., Nelsen L.M., et al.. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): A randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir. Med.. 2017;5 390–400. doi:10.1016/S2213-2600(17)30125-X
207. Bel E.H., Wenzel S.E., Thompson P.J., Prazma C.M., Keene O.N., Yancey S.W., et al.. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N. Engl. J. Med.. 2014;371 1189–1197. doi:10.1056/NEJMoa1403291
208. Bernstein J.A., Virchow J.C., Murphy K., Maspero J.F., Jacobs J., Adir Y., et al.. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: Results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir. Med.. 2020;8 461–474. doi:10.1016/S2213-2600(19)30372-8
209. Varricchi G., Senna G., Loffredo S., Bagnasco D., Ferrando M., Canonica G.W.. Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?. Front. Immunol.. 2017;8 242. doi:10.3389/fimmu.2017.00242
210. Bleecker E.R., FitzGerald J.M., Chanez P., Papi A., Weinstein S.F., Barker P., et al.. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388 2115–2127. doi:10.1016/S0140-6736(16)31324-1
211. Ferguson G.T., FitzGerald J.M., Bleecker E.R., Laviolette M., Bernstein D., LaForce C., et al.. Benralizumab for patients with mild to moderate, persistent asthma (BISE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med.. 2017;5 568–576. doi:10.1016/S2213-2600(17)30190-X
212. Casale T.B., Luskin A.T., Busse W., Zeiger R.S., Trzaskoma B., Yang M., et al.. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence from PROSPERO, A Prospective Real-World Study. J. Allergy Clin. Immunol. Pract.. 2019;7 156–164.e1. doi:10.1016/j.jaip.2018.04.043
213. Gasser P., Tarchevskaya S.S., Guntern P., Brigger D., Ruppli R., Zbaren N., et al.. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat. Commun.. 2020;11 165. doi:10.1038/s41467-019-13815-w
214. Braithwaite I.E., Cai F., Tom J.A., Galanter J.M., Owen R.P., Zhu R., et al.. Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial. J. Allergy Clin. Immunol.. 2021;148 783–789. doi:10.1016/j.jaci.2021.02.042
215. Schanin J., Luu T., Korver W., Brock E.C., Benet Z., Xu A., et al.. An Agonistic Monoclonal Antibody Against Siglec-6 Selectively Inhibits and Reduces Human Tissue Mast Cells. 2022
216. Wilkinson T., Dixon R., Page C., Carroll M., Griffiths G., Ho L.P., et al.. ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21 691. doi:10.1186/s13063-020-04584-9
217. Ballantyne S.J., Barlow J.L., Jolin H.E., Nath P., Williams A.S., Chung K.F., et al.. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J. Allergy Clin. Immunol.. 2007;120 1324–1331. doi:10.1016/j.jaci.2007.07.051
218. Busse W.W., Morgan W.J., Gergen P.J., Mitchell H.E., Gern J.E., Liu A.H., et al.. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N. Engl. J. Med.. 2011;364 1005–1015. doi:10.1056/NEJMoa1009705
219. Beck L.A., Marcotte G.V., MacGlashan D., Togias A., Saini S.. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J. Allergy Clin. Immunol.. 2004;114 527–530. doi:10.1016/j.jaci.2004.06.032
220. Hanania N.A., Alpan O., Hamilos D.L., Condemi J.J., Reyes-Rivera I., Zhu J., et al.. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial. Ann. Intern. Med.. 2011;154 573–582. doi:10.7326/0003-4819-154-9-201105030-00002
221. Normansell R., Walker S., Milan S.J., Walters E.H., Nair P.. Omalizumab for asthma in adults and children. Cochrane Database Syst. Rev.. 2014;13 CD003559. doi:10.1002/14651858.CD003559.pub4
222. Hew M., Gillman A., Sutherland M., Wark P., Bowden J., Guo M., et al.. Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. Clin. Exp. Allergy. 2016;46 1407–1415. doi:10.1111/cea.12774
223. Alhossan A., Lee C.S., MacDonald K., Abraham I.. “Real-life” Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis. J. Allergy Clin. Immunol. Pract.. 2017;5 1362–1370.e2. doi:10.1016/j.jaip.2017.02.002
224. Esquivel A., Busse W.W., Calatroni A., Togias A.G., Grindle K.G., Bochkov Y.A., et al.. Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. Am. J. Respir. Crit. Care Med.. 2017;196 985–992. doi:10.1164/rccm.201701-0120OC
225. Pelaia C., Calabrese C., Terracciano R., de Blasio F., Vatrella A., Pelaia G.. Omalizumab, the first available antibody for biological treatment of severe asthma: More than a decade of real-life effectiveness. Ther. Adv. Respir. Dis.. 2018;12 1753466618810192. doi:10.1177/1753466618810192
226. Pennington L.F., Tarchevskaya S., Brigger D., Sathiyamoorthy K., Graham M.T., Nadeau K.C., et al.. Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. Nat. Commun.. 2016;7 11610. doi:10.1038/ncomms11610
227. Cruse G., Yin Y., Fukuyama T., Desai A., Arthur G.K., Baumer W., et al.. Exon skipping of FcepsilonRIbeta eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy. Proc. Natl. Acad. Sci. USA. 2016;113 14115–14120. doi:10.1073/pnas.1608520113
228. Kambayashi T., Koretzky G.A.. Proximal signaling events in Fc epsilon RI-mediated mast cell activation. J. Allergy Clin. Immunol. 2007;119 544–552. doi:10.1016/j.jaci.2007.01.017
229. Villoutreix B.O., Laconde G., Lagorce D., Martineau P., Miteva M.A., Dariavach P.. Tyrosine kinase syk non-enzymatic inhibitors and potential anti-allergic drug-like compounds discovered by virtual and in vitro screening. PLoS ONE. 2011;6 doi:10.1371/journal.pone.0021117
230. Hayashi H., Kaneko R., Demizu S., Akasaka D., Tayama M., Harada T., et al.. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models. J. Pharmacol. Exp. Ther.. 2018;366 84–95. doi:10.1124/jpet.118.248153
231. Ramis I., Otal R., Carreno C., Domenech A., Eichhorn P., Orellana A., et al.. A novel inhaled Syk inhibitor blocks mast cell degranulation and early asthmatic response. Pharmacol. Res.. 2015;99 116–124. doi:10.1016/j.phrs.2015.05.011
232. Tabeling C., Herbert J., Hocke A.C., Lamb D.J., Wollin S.L., Erb K.J., et al.. Spleen tyrosine kinase inhibition blocks airway constriction and protects from Th2-induced airway inflammation and remodeling. Allergy. 2017;72 1061–1072. doi:10.1111/all.13101
233. Strich J.R., Ramos-Benitez M.J., Randazzo D., Stein S.R., Babyak A., Davey R.T., et al.. Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic. J. Infect. Dis.. 2021;223 981–984. doi:10.1093/infdis/jiaa789
234. Koziol-White C.J., Jia Y., Baltus G.A., Cooper P.R., Zaller D.M., Crackower M.A., et al.. Inhibition of spleen tyrosine kinase attenuates IgE-mediated airway contraction and mediator release in human precision cut lung slices. Br. J. Pharmacol.. 2016;173 3080–3087. doi:10.1111/bph.13550
235. Meltzer E.O., Berkowitz R.B., Grossbard E.B.. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J. Allergy Clin. Immunol.. 2005;115 791–796. doi:10.1016/j.jaci.2005.01.040
236. Guyer B.J., Shimamoto S.R., Bradhurst A.L., Grossbard E.B., Dreskin S.C., Nelson H.S.. Mast cell inhibitor R112 is well tolerated and affects prostaglandin D2 but not other mediators, symptoms, or nasal volumes in a nasal challenge model of allergic rhinitis. Allergy Asthma Proc.. 2006;27 208–213. doi:10.2500/aap.2006.27.2861
237. Awan F.T., Addison D., Alfraih F., Baratta S.J., Campos R.N., Cugliari M.S., et al.. International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL. Blood Adv.. 2022;6 5516–5525. doi:10.1182/bloodadvances.2022007938
238. Dispenza M.C., Krier-Burris R.A., Chhiba K.D., Undem B.J., Robida P.A., Bochner B.S.. Bruton’s tyrosine kinase inhibition effectively protects against human IgE-mediated anaphylaxis. J. Clin. Invest.. 2020;130 4759–4770. doi:10.1172/JCI138448
239. Dispenza M.C., Pongracic J.A., Singh A.M., Bochner B.S.. Short-term ibrutinib therapy suppresses skin test responses and eliminates IgE-mediated basophil activation in adults with peanut or tree nut allergy. J. Allergy Clin. Immunol.. 2018;141 1914–1916.e7. doi:10.1016/j.jaci.2017.12.987
240. Morita H., Matsumoto K., Saito H.. Biologics for allergic and immunologic diseases. J. Allergy Clin. Immunol.. 2022;150 766–777. doi:10.1016/j.jaci.2022.08.009
241. Youngblood B.A., Brock E.C., Leung J., Falahati R., Bryce P.J., Bright J., et al.. AK002, a Humanized Sialic Acid-Binding Immunoglobulin-Like Lectin-8 Antibody that Induces Antibody-Dependent Cell-Mediated Cytotoxicity against Human Eosinophils and Inhibits Mast Cell-Mediated Anaphylaxis in Mice. Int. Arch. Allergy Immunol.. 2019;180 91–102. doi:10.1159/000501637
242. Kerr S.C., Gonzalez J.R., Schanin J., Peters M.C., Lambrecht B.N., Brock E.C., et al.. An anti-siglec-8 antibody depletes sputum eosinophils from asthmatic subjects and inhibits lung mast cells. Clin. Exp. Allergy. 2020;50 904–914. doi:10.1111/cea.13681
243. Schanin J., Gebremeskel S., Korver W., Falahati R., Butuci M., Haw T.J., et al.. A monoclonal antibody to Siglec-8 suppresses non-allergic airway inflammation and inhibits IgE-independent mast cell activation. Mucosal Immunol.. 2021;14 366–376. doi:10.1038/s41385-020-00336-9
244. Dellon E.S., Peterson K.A., Murray J.A., Falk G.W., Gonsalves N., Chehade M., et al.. Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis. N. Engl. J. Med.. 2020;383 1624–1634. doi:10.1056/NEJMoa2012047
245. Bhasin S., Gill T.M., Reuben D.B., Latham N.K., Ganz D.A., Greene E.J., et al.. A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries. N. Engl. J. Med.. 2020;383 129–140. doi:10.1056/NEJMoa2002183
246. Shehata Y., Sheikh A.. Farming, childhood allergy, and unpasteurised milk A review of; “Which aspects of the farming lifestyle explain the inwerse association with childhood allergy.” Perkin MR, Strachan DP. Prim. Care Respir. J.. 2007;16 59–60. doi:10.3132/pcrj.2007.00005
247. Bachelet I., Munitz A., Berent-Maoz B., Mankuta D., Levi-Schaffer F.. Suppression of normal and malignant kit signaling by a bispecific antibody linking kit with CD300a. J. Immunol.. 2008;180 6064–6069. doi:10.4049/jimmunol.180.9.6064
248. Eggel A., Buschor P., Baumann M.J., Amstutz P., Stadler B.M., Vogel M.. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein. Allergy. 2011;66 961–968. doi:10.1111/j.1398-9995.2011.02546.x
249. Kim B., Eggel A., Tarchevskaya S.S., Vogel M., Prinz H., Jardetzky T.S.. Accelerated disassembly of IgE-receptor complexes by a disruptive macromolecular inhibitor. Nature. 2012;491 613–617. doi:10.1038/nature11546
250. Arock M., Hoermann G., Sotlar K., Hermine O., Sperr W.R., Hartmann K., et al.. Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022. J. Allergy Clin. Immunol.. 2022;149 1855–1865. doi:10.1016/j.jaci.2022.04.004
251. Arock M., Sotlar K., Akin C., Broesby-Olsen S., Hoermann G., Escribano L., et al.. KIT mutation analysis in mast cell neoplasms: Recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015;29 1223–1232. doi:10.1038/leu.2015.24
252. Valent P., Akin C., Bonadonna P., Hartmann K., Brockow K., Niedoszytko M., et al.. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. J. Allergy Clin. Immunol. Pract.. 2019;7 1125–1133. doi:10.1016/j.jaip.2019.01.006
253. Fonseca W., Rasky A.J., Ptaschinski C., Morris S.H., Best S.K.K., Phillips M., et al.. Group 2 innate lymphoid cells (ILC2) are regulated by stem cell factor during chronic asthmatic disease. Mucosal Immunol.. 2019;12 445–456. doi:10.1038/s41385-018-0117-1
254. Ptaschinski C., Rasky A.J., Fonseca W., Lukacs N.W.. Stem Cell Factor Neutralization Protects From Severe Anaphylaxis in a Murine Model of Food Allergy. Front. Immunol.. 2021;12 604192. doi:10.3389/fimmu.2021.604192
255. Brandt E.B., Strait R.T., Hershko D., Wang Q., Muntel E.E., Scribner T.A., et al.. Mast cells are required for experimental oral allergen-induced diarrhea. J. Clin. Invest.. 2003;112 1666–1677. doi:10.1172/JCI19785
256. Terhorst-Molawi D., Hawro T., Grekowitz E., Kiefer L., Metz M., Alvarado D., et al.. The Anti-KIT Antibody, CDX-0159, Reduces Mast Cell Numbers and Circulating Tryptase and Improves Disease Control in Patients with Chronic Inducible Urticaria (Cindu). J. Allergy Clin. Immunol.. 2022;149 AB178. doi:10.1016/j.jaci.2021.12.587
257. Rasky A., Habiel D.M., Morris S., Schaller M., Moore B.B., Phan S., et al.. Inhibition of the stem cell factor 248 isoform attenuates the development of pulmonary remodeling disease. Am. J. Physiol. Lung. Cell Mol. Physiol.. 2020;318 L200–L211. doi:10.1152/ajplung.00114.2019
258. Maurer M., Khan D.A., Elieh Ali Komi D., Kaplan A.P.. Biologics for the Use in Chronic Spontaneous Urticaria: When and Which. J. Allergy Clin. Immunol. Pract.. 2021;9 1067–1078. doi:10.1016/j.jaip.2020.11.043
259. Alvarado D., Maurer M., Gedrich R., Seibel S.B., Murphy M.B., Crew L., et al.. Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study. Allergy. 2022;77 2393–2403. doi:10.1111/all.15262
260. Valent P., Akin C., Hartmann K., Reiter A., Gotlib J., Sotlar K., et al.. Drug-induced mast cell eradication: A novel approach to treat mast cell activation disorders?. J. Allergy Clin. Immunol.. 2022;149 1866–1874. doi:10.1016/j.jaci.2022.04.003
261. Kolkhir P., Elieh-Ali-Komi D., Metz M., Siebenhaar F., Maurer M.. Understanding human mast cells: Lesson from therapies for allergic and non-allergic diseases. Nat. Rev. Immunol.. 2022;22 294–308. doi:10.1038/s41577-021-00622-y
262. Cahill K.N., Katz H.R., Cui J., Lai J., Kazani S., Crosby-Thompson A., et al.. KIT Inhibition by Imatinib in Patients with Severe Refractory Asthma. N. Engl. J. Med.. 2017;376 1911–1920. doi:10.1056/NEJMoa1613125
263. Chanez P., Israel E., Davidescu L., Ursol G., Korzh O., Deshmukh V., et al.. Abstract: Masitinib significantly decreases the rate of asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids: A phase 3 multicenter study. Am. J. Respir. Crit. Care Med.. 2020;201 A4210.
264. Humbert M., de Blay F., Garcia G., Prud’homme A., Leroyer C., Magnan A., et al.. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy. 2009;64 1194–1201. doi:10.1111/j.1398-9995.2009.02122.x
265. Lee-Fowler T.M., Guntur V., Dodam J., Cohn L.A., DeClue A.E., Reinero C.R.. The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma. Int. Arch. Allergy Immunol.. 2012;158 369–374. doi:10.1159/000335122
266. Vaali K., Lappalainen J., Lin A.H., Mayranpaa M.I., Kovanen P.T., Berstad A., et al.. Imatinib mesylate alleviates diarrhea in a mouse model of intestinal allergy. Neurogastroenterol. Motil.. 2012;24 e325–e335. doi:10.1111/j.1365-2982.2012.01941.x
267. Jung S.H., Sun X., Ryu W.S., Yang B.S.. Topical administration of the pan-Src kinase inhibitors, dasatinib and LCB 03-0110, prevents allergic contact dermatitis in mice. Br. J. Dermatol.. 2013;168 112–119. doi:10.1111/bjd.12069
268. da Silva A.L., Magalhaes R.F., Branco V.C., Silva J.D., Cruz F.F., Marques P.S., et al.. The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma. Br. J. Pharmacol.. 2016;173 1236–1247. doi:10.1111/bph.13430
269. Gotlib J., Reiter A., Radia D.H., Deininger M.W., George T.I., Panse J., et al.. Efficacy and safety of avapritinib in advanced systemic mastocytosis: Interim analysis of the phase 2 PATHFINDER trial. Nat. Med.. 2021;27 2192–2199. doi:10.1038/s41591-021-01539-8
270. DeAngelo D.J., Radia D.H., George T.I., Robinson W.A., Quiery A.T., Drummond M.W., et al.. Safety and efficacy of avapritinib in advanced systemic mastocytosis: The phase 1 EXPLORER trial. Nat. Med.. 2021;27 2183–2191. doi:10.1038/s41591-021-01538-9
271. Kneidinger M., Schmidt U., Rix U., Gleixner K.V., Vales A., Baumgartner C., et al.. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008;111 3097–3107. doi:10.1182/blood-2007-08-104372
272. Peter B., Winter G.E., Blatt K., Bennett K.L., Stefanzl G., Rix U., et al.. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Leukemia. 2016;30 464–472. doi:10.1038/leu.2015.242
273. Krauth M.T., Mirkina I., Herrmann H., Baumgartner C., Kneidinger M., Valent P.. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin. Exp. Allergy. 2009;39 1711–1720. doi:10.1111/j.1365-2222.2009.03353.x
274. Savage J.H., Courneya J.P., Sterba P.M., Macglashan D.W., Saini S.S., Wood R.A.. Kinetics of mast cell, basophil, and oral food challenge responses in omalizumab-treated adults with peanut allergy. J. Allergy Clin. Immunol.. 2012;130 1123–1129.e2. doi:10.1016/j.jaci.2012.05.039
275. Ishizaka K., Ishizaka T., Hornbrook M.M.. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J. Immunol.. 1966;97 75–85.
276. Johansson S.G., Bennich H.. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology. 1967;13 381–394.
277. Varricchi G., Pecoraro A., Loffredo S., Poto R., Rivellese F., Genovese A., et al.. Heterogeneity of Human Mast Cells With Respect to MRGPRX2 Receptor Expression and Function. Front. Cell Neurosci.. 2019;13 299. doi:10.3389/fncel.2019.00299
278. Vivanco Gonzalez N., Oliveria J.P., Tebaykin D., Ivison G.T., Mukai K., Tsai M.M., et al.. Mass Cytometry Phenotyping of Human Granulocytes Reveals Novel Basophil Functional Heterogeneity. iScience. 2020;23 101724. doi:10.1016/j.isci.2020.101724
279. Derakhshan T., Boyce J.A., Dwyer D.F.. Defining mast cell differentiation and heterogeneity through single-cell transcriptomics analysis. J. Allergy Clin. Immunol.. 2022;150 739–747. doi:10.1016/j.jaci.2022.08.011
280. Heijink I.H., Kuchibhotla V.N.S., Roffel M.P., Maes T., Knight D.A., Sayers I., et al.. Epithelial cell dysfunction, a major driver of asthma development. Allergy. 2020;75 1902–1917. doi:10.1111/all.14421
281. Cohen M., Giladi A., Gorki A.D., Solodkin D.G., Zada M., Hladik A., et al.. Lung Single-Cell Signaling Interaction Map Reveals Basophil Role in Macrophage Imprinting. Cell. 2018;175 1031–1044.e18. doi:10.1016/j.cell.2018.09.009
282. Aegerter H., Lambrecht B.N., Jakubzick C.V.. Biology of lung macrophages in health and disease. Immunity. 2022;55 1564–1580. doi:10.1016/j.immuni.2022.08.010
283. Balestrieri B., Granata F., Loffredo S., Petraroli A., Scalia G., Morabito P., et al.. Phenotypic and Functional Heterogeneity of Low-Density and High-Density Human Lung Macrophages. Biomedicines. 2021;9 doi:10.3390/biomedicines9050505
284. MacGlashan D., Saini S., Schroeder J.T.. Response of peripheral blood basophils in subjects with chronic spontaneous urticaria during treatment with omalizumab. J. Allergy Clin. Immunol.. 2021;147 2295–2304.e12. doi:10.1016/j.jaci.2021.02.039
285. Lommatzsch M., Marchewski H., Schwefel G., Stoll P., Virchow J.C., Bratke K.. Benralizumab strongly reduces blood basophils in severe eosinophilic asthma. Clin. Exp. Allergy. 2020;50 1267–1269. doi:10.1111/cea.13720
286. Galli S.J., Gaudenzio N., Tsai M.. Mast Cells in Inflammation and Disease: Recent Progress and Ongoing Concerns. Annu. Rev. Immunol.. 2020;38 49–77. doi:10.1146/annurev-immunol-071719-094903

Where this page came from

This page was imported from International Journal of Molecular Sciences (PubMed Central). “Human Lung Mast Cells: Therapeutic Implications in Asthma” by Remo Poto, Gjada Criscuolo, Gianni Marone et al., International Journal of Molecular Sciences (2022), doi:10.3390/ijms232214466, published under CC BY 4.0. Changed here: set as a page from the journal’s XML, its supplementary files left out; figures the article marks as reproduced under other terms are left out.

Nobody has written it yet — it is the source material at a new address, which is why search engines are asked to skip it and why no one earns from it. It is up for grabs: take it on, and it is yours to rewrite and to earn from.